RE: Early reaction to RNS5 Jan 2023 16:29
I would underline Ferdinand's comments; as I read it, the initial debt to Oxford Finance has not been paid off, it has been bought out and extended by Armistice, it is still repayable, the net position has not changed, 4D shareholders simply owe it to someone else, now Armistice, an entity who will now hold millions of shares and/or options for the privilege; indeed Armistice has the right to ensure that up to 50% of the $15m capital raised is used to fund the repayment of the loan....and even if they do the outstanding 50% will still need repaying at some point. If Armistice insist on converting the warrants to do so, they will then become the de facto owner of 4D Pharma. To avoid this happening where does 4D pharma (with no income) get the capital to repay the outstanding loan or the interest on it (deferred until 31 March 2024)? It appears that we have simply pushed the Oxford Finance scenario further into the future and we will rely upon further capital raises before that date to satisfy our obligations or passing control to Armistice.
So let's make sure there is no "double counting" here. Armistice have not "invested " $30m for their warrants.